Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS Granted US Patent for QUALIPHI®

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
New patent opens SYGNIS and QUALIPHI® in a leading position in a €70 million global market.

SYGNIS Pharma AG has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI® the polymerase for complete DNA amplification.

Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.

QUALIPHI® is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market.

Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.

“Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalized medicine and NGS. We expect QUALIPHI® to become an essential tool for the DNA amplification needed in these markets”, said SYGNIS’ CEO, Pilar de la Huerta.

With the significant growth in the field of DNA amplifications used in sequencing and personalized medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years.

Current estimates indicate that the size of the global isothermal DNA market alone is approximately €70 million, with the US as the leading market for QUALIPHI®.

In 2012,SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI® in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!